Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines

• Published in: Trends in pharmacological sciences (Regular ed.) Vol. 14; no. 9; pp. 325 - 331
• Main Author: Rogawski, Michael A.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.09.1993; Elsevier Science
• Subjects: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid - antagonists & inhibitors; Animals; Anti-Anxiety Agents; Anticonvulsants - therapeutic use; Benzodiazepines - pharmacology; Benzodiazepines - therapeutic use; Biological and medical sciences; Central Nervous System Diseases - drug therapy; Humans; Ion Channels - antagonists & inhibitors; Medical sciences; Miscellaneous; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Pharmacology. Drug treatments; Receptors, Kainic Acid - antagonists & inhibitors; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors; AMPA; GYKI52466; ADCI; NBQX; AMPA receptor; Structure activity relation; Anticonvulsant; Glutamate receptor; Neuroprotective agent; Antagonist; Antiïschemic; Review; NMDA receptor; Kainate receptor
• ISSN: 0165-6147; 1873-3735
• DOI: 10.1016/0165-6147(93)90005-5

NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/ kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neuro-degeneration and Parkinson's disease.